EP Patent
EP3444261B1 — 2,2-difluoropropionamide derivative of bardoxolone methyl, pharmaceutical compositions and polymorphs thereof for use in treating certain conditions
Assigned to Reata Pharmaceuticals Inc · Expires 2021-01-13 · 5y expired
What this patent protects
Patent listed against Skyclarys.
Drugs covered by this patent
- Skyclarys (OMAVELOXOLONE) · Biogen Us
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.